Ultragenyx Pharmaceutical Inc (RARE)

69.36
1.26 1.85
NASDAQ : Health Care
Prev Close 68.10
Open 68.53
Day Low/High 67.94 / 70.60
52 Wk Low/High 46.52 / 133.40
Volume 856.08K
Avg Volume 707.50K
Exchange NASDAQ
Shares Outstanding 39.44M
Market Cap 2.60B
EPS -4.00
P/E Ratio 25.29
Div & Yield N.A. (N.A)

Latest News

These 5 Stocks Are Breaking Out This Summer

These 5 Stocks Are Breaking Out This Summer

These five technical setups are showing solid upside potential right now.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposiumâ„¢

Ultragenyx Announces Data Presentations Of RhGUS And RhPPCA At 12th Annual WORLD Symposiumâ„¢

Ultragenyx CEO Emil Kakkis, M.D. Ph.D., Receives 2016 Lysosomal Disease Network Award for Innovation and Achievement

Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink

Ultragenyx Pharmaceutical (RARE) Stock Gets 'Outperform' Rating at Leerink

Leerink began coverage of Ultragenyx Pharmaceutical (RARE) stock with an 'outperform' rating and $80 price target on Friday morning.

Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia

Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia

Substantial Reduction in Bone Disease Demonstrated With Two Different Instruments